Critically, these strategies cannot be applied indiscriminately; rather, their clinical utility depends on a precision medicine approach that stratifies patients based on the distinct molecular vulnerabilities created by the tumor’s p53 functional status (Figure 5). The gene discussed is TP53; the disease is neoplasm.